Literature DB >> 16133366

Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid.

Katsuaki Sato1, Yoshimichi Ueda, Keiichi Ueno, Kazuya Okamoto, Hideaki Iizuka, Shogo Katsuda.   

Abstract

We report a case of hepatocellular carcinoma (HCC) arising in nonalcoholic steatohepatitis (NASH). The patient, a 64-year-old man, was incidentally found to have multiple tumors in the liver when admitted for pneumonia. He had been obese, had been receiving a standard dose of valproic acid since clipping surgery for subarachnoid hemorrhage 17 years previously, and had not consumed any alcohol since the surgery. Laboratory data revealed moderate hyperlipidemia and no evidence of diabetes mellitus, hepatitis B or C infection. The patient died of hepatic insufficiency, and an autopsy was performed. A tumor, a maximum of 13 cm in diameter, grossly occupied the entire left lobe and one third of the right lobe of the liver. Histologically, moderately differentiated HCC was found with foci of poorly differentiated HCC. The non-tumorous area showed NASH with moderate bridging fibrosis, without interface hepatitis, hemochromatosis, or copper accumulation. In this patient, obesity, hyperlipidemia, and long-term treatment with valproic acid could have all been associated with induction of NASH. The present case suggests that HCC could develop in non-cirrhotic NASH liver, and that chronic inflammation in itself could be an important risk factor in the development of HCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16133366     DOI: 10.1007/s00428-005-0042-z

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  23 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

2.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

Authors:  Elisabetta Bugianesi; Nicola Leone; Ester Vanni; Giulio Marchesini; Franco Brunello; Patrizia Carucci; Alessandro Musso; Paolo De Paolis; Lorenzo Capussotti; Mauro Salizzoni; Mario Rizzetto
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

3.  Lipid-rich clear-cell hepatocellular carcinoma arising in non-alcoholic steatohepatitis in a patient with diabetes mellitus.

Authors:  H Orikasa; R Ohyama; N Tsuka; B P Eyden; K Yamazaki
Journal:  J Submicrosc Cytol Pathol       Date:  2001 Jan-Apr

4.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.

Authors:  M Göttlicher; S Minucci; P Zhu; O H Krämer; A Schimpf; S Giavara; J P Sleeman; F Lo Coco; C Nervi; P G Pelicci; T Heinzel
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

5.  Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia.

Authors:  Zhenrong Xu; Linyun Chen; Laura Leung; T S Benedict Yen; Candy Lee; Jefferson Y Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-28       Impact factor: 11.205

Review 6.  Obesity and hepatocellular carcinoma.

Authors:  Stephen H Caldwell; Deborah M Crespo; Hyon Scott Kang; Abdullah M S Al-Osaimi
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

Review 7.  Drugs and steatohepatitis.

Authors:  Geoffrey C Farrell
Journal:  Semin Liver Dis       Date:  2002       Impact factor: 6.115

8.  Hepatocellular carcinoma arising in non-alcoholic steatohepatitis.

Authors:  Y Zen; K Katayanagi; K Tsuneyama; K Harada; I Araki; Y Nakanuma
Journal:  Pathol Int       Date:  2001-02       Impact factor: 2.534

Review 9.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 10.  Hepatocellular carcinoma with nonalcoholic steatohepatitis.

Authors:  Sayaka Mori; Takahiro Yamasaki; Isao Sakaida; Taro Takami; Eiki Sakaguchi; Teruaki Kimura; Fumie Kurokawa; Shiro Maeyama; Kiwamu Okita
Journal:  J Gastroenterol       Date:  2004       Impact factor: 7.527

View more
  5 in total

Review 1.  Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review.

Authors:  Yoshitaka Takuma; Kazuhiro Nouso
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

2.  Multicentric occurrence of hepatocellular carcinoma with nonalcoholic steatohepatitis.

Authors:  Hirokazu Kawai; Minoru Nomoto; Takeshi Suda; Kenya Kamimura; Atsunori Tsuchiya; Yasushi Tamura; Masahiko Yano; Masaaki Takamura; Masato Igarashi; Toshifumi Wakai; Satoshi Yamagiwa; Yasunobu Matsuda; Shogo Ohkoshi; Isao Kurosaki; Yoshio Shirai; Masahiko Okada; Yutaka Aoyagi
Journal:  World J Hepatol       Date:  2011-01-27

3.  Nonalcoholic fatty liver disease during valproate therapy.

Authors:  Alberto Verrotti; Giovanna Di Marco; Rosanna la Torre; Piernicola Pelliccia; Francesco Chiarelli
Journal:  Eur J Pediatr       Date:  2009-01-30       Impact factor: 3.183

4.  Association between antiepileptic drugs and hepatocellular carcinoma in patients with epilepsy: a population-based case-control study.

Authors:  Dong-Zong Hung; Cheng-Li Lin; Yi-Wen Li; Yen-Ning Lin; Ying-Ray Lee; Charles-C N Wang; Jih-Jung Chen; Yun-Ping Lim
Journal:  Brain Behav       Date:  2016-09-12       Impact factor: 2.708

Review 5.  Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?

Authors:  Alex Claveria-Cabello; Leticia Colyn; Maria Arechederra; Jesus M Urman; Carmen Berasain; Matias A Avila; Maite G Fernandez-Barrena
Journal:  Cells       Date:  2020-10-19       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.